To establish current uro-oncology practice in the management of sexual dysfunction following radiotherapy and/or androgen deprivation therapy to treat prostate cancer. To identify differences in approach to the management of sexual dysfunction according to disease stage.
A 14-question mixed methods survey was designed to assess current UK practice. Closed and open-ended questions were used to quantify results while allowing participants to expand on answers. The survey was distributed to members of the British Uro-Oncology Group at the 2019 annual meeting.
Surveys were completed by 63 uro-oncologists attending the annual meeting of the British Uro-Oncology Group (response rate 66%). The major issue highlighted was a difference in approach to managing sexual dysfunction according to disease stage. More than half of participants (56%) said ‘advanced stage of disease’ was a barrier to discussing sexual dysfunction. Clinicians were less likely to discuss sexual dysfunction, take baseline assessments, refer to a specialist clinic or offer rehabilitation when dealing with patients with advanced disease. Only a minority said the management sexual dysfunction was primarily their responsibility (11%). Nearly all clinicians (92%) had access to sexual dysfunction clinics however the majority of clinicians did not routinely refer patients.
This study shows men with advanced prostate cancer need better support in managing sexual dysfunction. Patients receiving long-term ADT are less likely to be offered any kind of help or intervention. Specific guidance on managing sexual dysfunction in this cohort may result in improvements in sexual function, emotional wellbeing, quality of life, mental health and confidence.

This article is protected by copyright. All rights reserved.